Biophytis Gains Momentum; bluebird bio Posts Mixed Results
- August 08th, 2023
- 399 views
Shares of Biophytis S.A. (Nasdaq: BPTS) surged over 10% in pre-market trading as the company secured a favorable opinion from Belgian authorities for its groundbreaking SARA-31 program.
This initiative marks the first-ever phase 3 study targeting sarcopenia, a neuromuscular ailment prevalent among the elderly, characterized by muscle strength decline and mobility loss, thereby impacting autonomy and life expectancy.
In pre-market, $BPTS was trading at $1.73, reflecting a substantial increase of $0.18 (+11.61%).
Meanwhile, bluebird bio, Inc. (Nasdaq: BLUE) has announced its second-quarter 2023 financial results, posting a loss of $0.67 per share. Although the loss was slightly better than the consensus estimate of $0.71 per share, the company's quarterly sales totaled $6.89 million, falling short of the analysts' projected revenue of $11.65 million for the period.
$BLUE was trading at $3.55 in pre-market, down $0.05 (-1.39%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login